To read the full story, subscribe or sign in.

Paradigm's AU$16M moves Zilosul to pivotal osteoarthritis trials

Dec. 9, 2024

Paradigm Biopharmaceuticals Ltd. raised AU$16 million (US$10.31 million) in a placement that will allow the company to start a global phase III trial with its lead product, Zilosul (injectable pentosan polysulfate/iPPS), to treat osteoarthritis.

BioWorld Clinical Financings Inflammatory Musculoskeletal Mezzanine Asia-Pacific Australia FDA

Today's news in brief

BioWorld

BioWorld briefs for Nov. 14, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Nov. 14, 2025.

Deal handshake with coin, chart background

ABL Bio’s Grabody lands second $2.6B deal, this time with Lilly

BioWorld

ABL Bio Inc. inked a license and research agreement with Eli Lilly and Co. worth up to $2.6 billion to develop multiple therapeutics using the Grabody-B platform....

Illustration of magnifying glass inspecting brain

Anchoring, and bootstrapping, psychiatry into the precision medicine era

BioWorld Science

Psychiatry has struggled to enter the precision medicine era. But through a mix of innovations and bootstrapping, progress is coming to the field. Scientists are...

With transdiagnostic approach, smaller target groups aren’t inevitably smaller markets

BioWorld

Despite the formidable challenges for developing precision psychiatry, the approach is notching its first successes in the preclinical and even some clinical...